Keliximab
Keliximab is a monoclonal antibody for the treatment of severe chronic asthma. It suppresses the immune reaction by binding to white blood cells via the protein CD4.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (primate/human) |
| Target | CD4 |
| Clinical data | |
| Routes of administration | intravenous |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
  | |
References
- Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC (October 1998). "Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma". Lancet. 352 (9134): 1109–13. doi:10.1016/S0140-6736(97)12261-9. PMID 9798587.
- "Proposed INN List" (PDF). WHO Drug Information. 10 (Number 4). 1996.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.